Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?

نویسندگان

  • M J Asmus
  • L Hendeles
چکیده

Albuterol is a 50:50 mixture of R-albuterol, the active enantiomer, and S-albuterol, which appears to be inactive in humans. The Food and Drug Administration recently approved levalbuterol, the pure R-isomer, as a preservative-free nebulizer solution. Published studies indicate that it is neither safer nor more effective than an equimolar dose of racemic albuterol (levalbuterol 1.25 mg = albuterol 2.5 mg). However, these studies were conducted in patients with stable asthma (at the top of the dose-response curve), whereas a nebulized bronchodilator most likely would be used by patients with an acute exacerbation. Because such patients, in the hospital setting, often require higher doses of albuterol, the manufacturer's recommended dose of levalbuterol is likely to be too low for rescue therapy. Levalbuterol may cost as much as 5 times more than racemic albuterol, depending on purchase method. We conclude that levalbuterol offers no advantage over albuterol but is likely to be more costly.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Clot burden and comorbidity in natural history of untreated pulmonary thromboembolism: autopsy data in the trial by Barritt and Jordan.

1 Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003; 123:128–135 2 Truitt TJ, Witko J, Kotter S, et al. Levalbuterol reduces total and breakthrough treatments in hospitalized patients [abstract]. Am J Respir Crit Care Med 2000; 161:A553 3 Academy of Managed Care Pharmacy. Format for formulary ...

متن کامل

Treatment with (R)-albuterol has no advantage over racemic albuterol.

70. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003;123:128–135. 71. Skoner DP, Greos LS, Kim LT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of levalbuterol in 2–5-year-old patients with asthma. Pediatr Pulmonol 2005;40:477–486. 72. Nelson HS, Bensch G, Pleskow...

متن کامل

Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma.

STUDY OBJECTIVES To compare clinical efficacy, patient outcomes, and medical costs in hospitalized patients treated with levalbuterol to those treated with racemic albuterol. DESIGN Retrospective chart review. SETTING A 180-bed community hospital. PATIENTS Patients admitted to Halifax Regional Hospital with a diagnosis code for COPD or asthma from July 1 to December 31, 1998, and from Jul...

متن کامل

Levalbuterol is not more cost-effective than albuterol for COPD.

In a recent issue of CHEST, Truitt et al (January 2003)1 claimed that their retrospective chart review demonstrated that “levalbuterol afforded clinical and pharmacoeconomic advantages over racemic albuterol” in the treatment of hospitalized patients with COPD and asthma. The primary end point of the study was the total number of nebulizer treatments required. However, the target care path that...

متن کامل

Comparison of levalbuterol and racemic albuterol based on cardiac adverse effects in children.

OBJECTIVE To compare the cardiac effects of levalbuterol with those of racemic albuterol based on changes in heart rate (HR) in pediatric patients. METHODS The medical records of hospitalized children ages 1 month to 12 years, who received either levalbuterol or racemic albuterol via nebulizer for 3 consecutive doses between January 2006 and December 2008 were reviewed. The documented HR was ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Pharmacotherapy

دوره 20 2  شماره 

صفحات  -

تاریخ انتشار 2000